Invesco International Dividend Achievers ETF (PID)
NASDAQ: PID · Real-Time Price · USD
23.23
-0.21 (-0.89%)
At close: Jul 31, 2026, 4:00 PM EDT
23.25
+0.02 (0.08%)
After-hours: Jul 31, 2026, 7:34 PM EDT
-0.89% (1D)
| Assets | $934.46M |
| Expense Ratio | 0.53% |
| PE Ratio | 13.84 |
| Shares Out | 39.85M |
| Dividend (ttm) | $0.80 |
| Dividend Yield | 3.45% |
| Ex-Dividend Date | Jun 22, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 47.73% |
| Volume | 43,376 |
| Open | 23.37 |
| Previous Close | 23.44 |
| Day's Range | 23.14 - 23.37 |
| 52-Week Low | 20.43 |
| 52-Week High | 23.76 |
| Beta | 0.72 |
| Holdings | 67 |
| Inception Date | Sep 15, 2005 |
About PID
Fund Home PageThe Invesco International Dividend Achievers ETF (PID) is an exchange-traded fund that mostly invests in total market equity. The fund tracks a dividend-yield-weighted index of foreign securities with high dividend growth. PID was launched on Sep 15, 2005 and is issued by Invesco.
Asset Class Equity
Category Foreign Large Value
Region Global
Stock Exchange NASDAQ
Ticker Symbol PID
ETF Provider Invesco
Index Tracked NASDAQ International Dividend Achiever Index
Top 10 Holdings
31.35% of assets| Name | Symbol | Weight |
|---|---|---|
| Itau Unibanco Holding SA ADR | BVXB.DE | 4.31% |
| PT Telkom Indonesia (Persero) Tbk ADR | PTI.DE | 3.55% |
| TELUS Corporation | T | 3.27% |
| Sanofi | SNY | 3.20% |
| FinVolution Group | FINV | 3.05% |
| Enbridge Inc. | ENB | 3.03% |
| British American Tobacco PLC ADR | BMTA.DE | 2.96% |
| Brookfield Infrastructure Partners L.P. | BIP | 2.77% |
| Eni S.p.A. | E | 2.72% |
| Emera Incorporated | EMA | 2.50% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 22, 2026 | $0.31287 | Jun 26, 2026 |
| Mar 23, 2026 | $0.19759 | Mar 27, 2026 |
| Dec 22, 2025 | $0.11851 | Dec 26, 2025 |
| Sep 22, 2025 | $0.17214 | Sep 26, 2025 |
| Jun 23, 2025 | $0.26366 | Jun 27, 2025 |
| Mar 24, 2025 | $0.16654 | Mar 28, 2025 |
Performance
PID had a total return of 16.83% in the past year, including dividends. Since the fund's inception, the average annual return has been 5.72%.
News
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in Primary Immunodeficiency Disease (PID) patients, met its primary endpoint.
Other symbols: TAK
3 months ago - Business Wire